stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) EPS (diluted)
Perrigo Company plc's EPS (diluted) for fiscal 2025 was −$10.29, compared with −$1.25 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$12.76. Over the past ten years it has ranged from −$28.01 (fiscal 2016) to $1.07 (fiscal 2019); the current reading is higher than 17% of that period. Perrigo Company plc ranks 69th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$10.29 | — |
| FY2024 | −$1.25 | — |
| FY2023 | −$0.09 | — |
| FY2022 | −$1.04 | — |
| FY2021 | −$0.52 | — |
| FY2020 | −$1.19 | — |
| FY2019 | $1.07 | 12.63% |
| FY2018 | $0.95 | 13.10% |
| FY2017 | $0.84 | — |
| FY2016 | −$28.01 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.20 | — |
| Jun 2026 | $0.53 | — |
| Mar 2026 | −$2.87 | — |
| Dec 2025 | −$10.22 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | $5.02 |
| PBH Prestige Consumer Healthcare Inc. compare | $3.24 |
| XERS Xeris Biopharma Holdings, Inc. compare | −$0.05 |
| ALVO Alvotech compare | −$1.24 |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$1.42 |
| TRLV Trulieve Cannabis Corp. compare | −$2.47 |
| PRGO Perrigo Company plc | −$12.76 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PRGO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement